Nicoletta Luppi graduates with a Honours Degree in Modern Languages & Literatures and then earns a Master's Degree in Business Administration from the "L.U.I.S.S." University School of Management in Rome.
In 1993 she joins MSD, covering a number of positions with increasing responsibilities, ranging from the lead of the Cardiovascular-Metabolic Franchise and the Joint Venture with Schering Plough, to the management of two sister Companies (Neopharmed and Gentili), up to creating and leading the Market Access & Commercial Operations, expanding her expertise throughout the entire wide portfolio of MSD products.
In 2012, she is appointed President and Managing Director of Sanofi Pasteur MSD, the European Joint Venture between Sanofi Pasteur – the Vaccine Division of Sanofi – and MSD Vaccine Division.
In recognition of her leadership in this role, she is awarded "CEO of the Year"- (Pharmaceutical Area, "Le Fonti" Award). She is also elected as President of the Vaccines Group in Farmindustria.
In 2015, she becomes President and Managing Director of MSD Italy, first woman ever to hold such role within the Italian affiliate of the Multinational Pharmaceutical Company Merck & Co.
In 2016 she is nominated President of the Alumni LUISS Business School Association.
In March 2017 (and for the following years), she is selected by AMREF to act as testimonial of the NGO’s social media campaign against female genital mutilations and, again in 2017, she is honoured with the prestigious award “Premio Minerva-Donna D’Eccellenza” in recognition of her leadership focused on creating an environment able to foster work-life balance, inclusion and diversity.
In 2018 she is nominated Senior Vice President in MSD.
At the end of 2019 she is appointed by Fortune Italy as “Businessperson of the Year 2019” (Pharmaceutical Category).
As of January 2020 she is selected as a member of the Board of Vaccines Europe and as a member of the Advisory Board “Kotler Impact Italia”.
She is also Lean Six Sigma Executive Belt.
Updated: August 2020